. 2022 Jul 3;25(8):104705. doi: 10.1016/j.isci.2022.104705

Table 1.

Overview of antigen binding, affinity, and neutralizing capacity of 20 selected antibodies

Antibody	ELISA antigen binding		Affinity K_D (pM)		Neutralization IC50 (nM)
Antibody	RBD (Wuhan)	Trimeric spike (Wuhan)	RBD (Wuhan)	Trimeric spike (Wuhan)	Trimeric spike (D614G)
*1A10*	+	+	*199 ± 58*	*89 ± 45*	*0.74*
1B11	+	+	443 ± 4	89 ± 18	/
*1C1*	+	+	*41 ± 12*	*44 ± 12*	*0.58*
*1C11*	+	+	*87 ± 24*	*84 ± 29*	*0.16*
1D5	+	+	111 ± 13	127 ± 78	7.37
1B5	+	+	45 ± 2	56 ± 16	1.86
2A2	+	+	220 ± 17	176 ± 88	26.22
2A8	+	+	78 ± 8	74 ± 5	8.35
*2B11*	+	+	*48 ± 21*	*32 ± 8*	*0.62*
*2B2*	+	+	*31 ± 7*	*63 ± 14*	*0.17*
2C8	+	+	64 ± 8	91 ± 15	/
2D10	+	+	52 ± 8	65 ± 36	23.38
*2D6*	+	+	*31 ± 6*	*69 ± 18*	*0.57*
3A11	+	+	58 ± 8	91 ± 18	17.37
3B3	+	+	252 ± 21	99 ± 18	/
*3B8*	+	+	*234 ± 104*	*86 ± 12*	*0.016*
3C11	+	+	48 ± 10	71 ± 11	13.71
*3E6*	+	+	*373 ± 295*	*243 ± 163*	*0.32*
3E9	+	+	248 ± 13	143 ± 20	0.97
3F9	+	+	98 ± 16	141 ± 168	/

Antigen binding was evaluated for RBD and trimeric spike protein (Wuhan) via ELISA (in duplicate) and SPR (minimum in triplicate). Affinity (K_D; in pM; average ±SD of at least three replicates) was determined via SPR. Neutralizing capacity is given in 50% inhibitory concentration (IC₅₀; in nM) and was measured in triplicate via a SARS-CoV-2 prototype (D614G) VSV pseudovirus assay. Bold and italic = 8 best neutralizing antibodies; + = potent antigen binding (OD ≥ 2) at mAb concentration of 1 μg/mL or lower; / = no neutralizing activity when tested at a concentration of 5 μg/mL or 33.34 nM.